AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
AstraZeneca PLC News & Analysis
markets
What are emerging and frontier markets?
Power blocs, frontier stocks and investor shocks explained as the world becomes more complex
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks
Best international companies to own: 2023 Edition
These companies from various corners of the globe are well positioned for the future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,126.90 | 2.50 | -0.03% |
CAC 40 | 7,742.73 | 43.81 | 0.57% |
DAX 40 | 23,824.10 | 227.12 | 0.96% |
Dow JONES (US) | 45,473.77 | 147.52 | -0.32% |
FTSE 100 | 9,232.92 | 24.71 | 0.27% |
HKSE | 25,633.91 | 215.93 | 0.85% |
NASDAQ | 21,870.43 | 162.73 | 0.75% |
Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
S&P 500 | 6,505.20 | 23.70 | 0.37% |
S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
SSE Composite Index | 3,826.84 | 14.33 | 0.38% |